Novo’s $3.3bn GalXC quest
The usually conservative group spends big on Dicerna – but others might be interested too.
What Novartis could buy with its windfall
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Centessa claims a place in the antitrypsin deficiency pipeline
But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.
Takeda gets the pipeline blues
A big selloff on a mid-stage stumble seems harsh, but Takeda has problems on the horizon.
Arrowhead pause raises more questions about lung delivery
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
Vertex clears the way for Arrowhead
As Arrowhead prepares to unveil key data in alpha-1 antitrypsin deficiency, its life is made easier by Vertex’s second failure in the disease.
